Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
07:55am, Tuesday, 12'th Aug 2025
Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference
07:00am, Monday, 11'th Aug 2025
NEW HAVEN, Conn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitat
Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLO
Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutica
Squarepoint Ops LLC Acquires 48,336 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)
03:36am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC grew its stake in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) by 203.9% during the fourth quarter, according to the company in its most recent 13F filing
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
07:00am, Tuesday, 27'th May 2025
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuro
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
09:15am, Monday, 12'th May 2025
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $2.72. This compares to loss of $13.92 per share a year ago.
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 12'th May 2025
Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
09:15am, Thursday, 27'th Mar 2025
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $3.57 per share versus the Zacks Consensus Estimate of a loss of $4.36. This compares to loss of $12.16 per share a year ago.
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
07:00am, Thursday, 27'th Mar 2025
Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or sch
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
03:16pm, Wednesday, 19'th Mar 2025
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI ® in the home setting
